Daniela Dinulescu, PhDBrigham and Women’s Hospital Nanotechology-based Therapy Targeting Platinum Resistant Disease An exciting new hypothesis in ovarian cancer biology is that tumor development is driven by cancer stem cells, which are resistant to standard chemotherapies and consequently responsible for the high rate of tumor relapse seen in patients. Animal models, which accurately recapitulate the […]
Read More
Xuefang Cao, MD, PhDRoswell Park Cancer Institute Granzyme B-Dependent Regulatory T Cell Function in Ovarian Cancer While effector lymphocytes are known to mediate anti-tumor immune responses, regulatory T cells (Tregs) have recently been found to promote tumor progression in ovarian cancer patients. Perforin and granzyme B are cytotoxic molecules previously known to be utilized by […]
Read More
Resham Bhattacharya, PhDMayo Clinic Therapeutic targeting of Bmi-1 in ovarian cancer While platinum-based drugs continue to be the foundation of therapy for ovarian cancer, chemoresistance remains the main challenge for effective management of recurrent disease. The development of new therapeutic strategies to combat ovarian cancer is needed. This study will examine the therapeutic potential of […]
Read More